Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.3.1.900
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 12 Months Ended
Oct. 31, 2013
USD ($)
ft²
Dec. 31, 2015
USD ($)
Milestone
Dec. 31, 2013
shares
Alachua Facility [Member]      
Commitment And Contingencies [Line Items]      
Period of expired lease   3 years  
Period of lease   5 years  
Expiration period   Dec. 31, 2014  
Rent expense   $ 123,000  
Tampa Facility [Member]      
Commitment And Contingencies [Line Items]      
Period of lease 39 months    
Expiration period   Feb. 28, 2017  
Rent expense   $ 78,000  
Area of Office Space Leased | ft² 4,168    
Minimum [Member] | Alachua Facility [Member]      
Commitment And Contingencies [Line Items]      
Monthly lease payments   9,641  
Minimum [Member] | Tampa Facility [Member]      
Commitment And Contingencies [Line Items]      
Monthly lease payments $ 6,426    
Maximum [Member] | Alachua Facility [Member]      
Commitment And Contingencies [Line Items]      
Monthly lease payments   $ 10,851  
Maximum [Member] | Tampa Facility [Member]      
Commitment And Contingencies [Line Items]      
Monthly lease payments $ 6,818    
UFRF License Agreement [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product   5.00%  
Company's obligation to pay from all revenue received from sublicenses   22.00%  
One-time commercialization fee monthly amount for calculation   $ 5,000  
Post-commercialization minimum royalty payments   50,000  
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount   $ 2,000,000  
One-time additional payment to UFRF as a percentage of total royalties due to UFRF   10.00%  
Minimum annual maintenance payment on license agreement   $ 10,000  
Quarterly maintenance payment to UFRF under installment plan   $ 2,500  
Termination notice period   90 days  
Texas A and M University License [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product   5.00%  
Post-commercialization minimum royalty payments   $ 100,000  
Termination notice period   90 days  
Initial payment to Texas A&M   $ 5,000  
Minimum consideration for the continuation of the license agreement   15,000  
Annual maintenance payment under licensing agreement with Texas A&M   $ 100,000  
Number of milestones achieved | Milestone   0  
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M   Jun. 01, 2019  
Milestone payment under licensing agreement   $ 100,000  
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M   Jun. 01, 2022  
Milestone payment under licensing agreement   $ 150,000  
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M   Jun. 01, 2016  
Milestone payment under licensing agreement   $ 50,000  
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M   Jun. 01, 2025  
Milestone payment under licensing agreement   $ 400,000  
Texas A and M University License [Member] | Minimum [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product   2.00%  
Lantibiotic ECC [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product   25.00%  
Company's obligation to pay from all revenue received from sublicenses   50.00%  
Termination notice period   90 days  
Number of milestones achieved | Milestone   0  
Number of shares issued | shares     4,392,425
Maximum percentage of primary investment securities to investment of shares issued   10.00%  
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares   1.00%  
Lantibiotic ECC [Member] | Phase 2 Clinical Trial [Member      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares   1.50%  
Lantibiotic ECC [Member] | Phase 3 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares   2.00%  
Lantibiotic ECC [Member] | New Drug Application or Biologics License Application [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares   2.50%  
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares   3.00%  
Oral Mucositis ECC [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product   12.00%  
Company's obligation to pay from all revenue received from sublicenses   50.00%  
Termination notice period   90 days  
Number of milestones achieved | Milestone   0  
Oral Mucositis ECC [Member] | Phase II Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 2,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | Phase 2b/3 Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 5,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 5,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | Approval Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 10,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 5,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement   $ 5,000,000  
Milestone measurement period   30 days  
Oral Mucositis ECC [Member] | Maximum [Member]      
Commitment And Contingencies [Line Items]      
Maturity of interest bearing promissory note   12 months